![]()  | 
![]()  | ![]()  | 
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. | 
    
     
    
    
 
    
    
    
MKG, Mallinckrodt. OK, Lab rats, you know the name Mallinkrodt from all the reagents you use. But MKG is actually a fair size conglomerate which is re-shaping itself into a medical device/pharma company. They are divesting low(er) margin businesses and are well positioned in respiratory care (Nellcor, Puritan-Bennett) as well as generic and specialty pharma. Earnings are good and growing at close to 10%. Current P/E is 9. Market cap 1.7 Billion, less than most fluffy dot-coms making losses each quarter. Worth a look. RWR  | ||||||||||||||
 
        
 
  | 
    
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings | 
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI | 
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |